DBV Technologies' 15min chart triggers KDJ Golden Cross, Bullish Marubozu signal.

According to DBV Technologies's 15-minute chart, a KDJ Golden Cross and Bullish Marubozu were triggered on July 30, 2025 at 12:15. This indicates a shift in momentum towards the upside, with potential for further price increases. The market appears to be controlled by buyers, and it is likely that bullish momentum will continue.

DBV Technologies, a biopharmaceutical company focused on developing innovative products for the treatment of food allergies, logged a wider loss in its second quarter. The company reported a loss of $41.9 million, or 31 cents per share, compared to a loss of $33.1 million, or 34 cents per share, in the same period last year [1].

The loss was driven by higher research and development expenses, which increased by 26% compared to the same period last year. The company's operating income also increased by 26% due to a greater proportion of activities eligible for the Research tax credit. However, the net loss per share improved from $(0.34) in the same period last year to $(0.31) [3].

DBV Technologies has substantial doubts regarding its ability to continue as a going concern. The company estimates that its cash and cash equivalents are sufficient to fund its operations into the second quarter of 2026, given it received gross proceeds of $125.5 million on April 7 related to financing for its Viaskin Peanut patch [1].

The company's stock experienced high volatility on Tuesday, July 29, 2025, ending trading at $9.80. The stock gained 0.719% on the last trading day, rising from $9.73 to $9.80. During the last trading day, the stock fluctuated 13.15% from a day low at $9.66 to a day high of $10.93. The stock is expected to rise 4.68% during the next 3 months, with a 90% probability of holding a price between $8.46 and $12.48 at the end of this 3-month period [2].

On July 30, 2025, at 12:15, a KDJ Golden Cross and Bullish Marubozu were triggered on DBV Technologies's 15-minute chart, indicating a shift in momentum towards the upside and potential for further price increases. The market appears to be controlled by buyers, and it is likely that bullish momentum will continue [4].

DBV Technologies is advancing its Viaskin Peanut patch through various clinical trials, including the ongoing Phase 3 VITESSE study for children aged 4-7 and the COMFORT Toddlers supplemental safety study for ages 1-3. The company plans to submit a Biologics License Application (BLA) for the Viaskin Peanut patch in toddlers aged 1-3, supported by data from the EPITOPE Phase 3 study and the COMFORT Toddlers study [3].

References:
[1] https://www.marketwatch.com/story/dbv-technologies-logs-wider-loss-has-doubts-on-continuing-as-going-concern-d5ed0204
[2] https://stockinvest.us/stock/DBVT
[3] https://www.tradingview.com/news/tradingview:0427f758b1622:0-dbv-technologies-s-a-sec-10-q-report/
[4] TradingView